Predictive Oncology Inc. Files 10-Q for Q1 2024

TL;DR

<b>Predictive Oncology Inc. filed its Q1 2024 10-Q report, detailing its financial performance and corporate history.</b>

AI Summary

Predictive Oncology Inc. (AGPU) filed a Quarterly Report (10-Q) with the SEC on May 14, 2024. Predictive Oncology Inc. filed its 10-Q report for the period ending March 31, 2024. The company was formerly known as Skyline Medical Inc. and Precision Therapeutics Inc. The filing covers the first quarter of fiscal year 2024. The company's business address is in Pittsburgh, PA. The SIC code for the company is 3842 (Orthopedic, Prosthetic & Surgical Appliances & Supplies).

Why It Matters

For investors and stakeholders tracking Predictive Oncology Inc., this filing contains several important signals. This filing provides an update on the company's financial health and operational status for the first quarter of 2024. Understanding the company's historical name changes and current SIC code provides context for its business evolution and industry classification.

Risk Assessment

Risk Level: low — Predictive Oncology Inc. shows low risk based on this filing. The filing is a standard 10-Q, providing routine financial updates without immediate indicators of significant new risks or opportunities.

Analyst Insight

Monitor future filings for revenue growth and net income trends to assess the company's financial trajectory.

Key Numbers

• 2024-03-31 — Reporting Period End Date (10-Q filing)
• 2024-05-14 — Filing Date (10-Q filing)
• 331007393 — IRS Number (Company data)
• 001-36790 — SEC File Number (Filing values)

Key Players & Entities

• Predictive Oncology Inc. (company) — Filer name
• Skyline Medical Inc. (company) — Former company name
• Precision Therapeutics Inc. (company) — Former company name
• Pittsburgh, PA (location) — Business address

FAQ

Industry Context

Predictive Oncology Inc. operates within the healthcare sector, specifically in the area of orthopedic, prosthetic, and surgical appliances and supplies.

Regulatory Implications

The company is subject to SEC regulations for its periodic financial reporting, including the filing of 10-Q forms.

What Investors Should Do

1. Review the full 10-Q filing for detailed financial statements and management discussion.
2. Track future SEC filings for updates on revenue, expenses, and profitability.
3. Research the company's specific products and services within the SIC code 3842.

Key Dates

• 2024-03-31: Quarterly Period End — End of the reporting period for the 10-Q filing.
• 2024-05-14: Filing Date — Date the 10-Q was officially filed with the SEC.

Glossary

10-Q

A quarterly report required by the U.S. Securities and Exchange Commission (SEC). (Provides an update on the company's financial performance and condition between annual reports.)

SIC Code

Standard Industrial Classification code used to classify industries. (Helps categorize Predictive Oncology Inc. within the 'Orthopedic, Prosthetic & Surgical Appliances & Supplies' sector.)

Year-Over-Year Comparison

This is the first 10-Q filing for the fiscal year 2024, providing an update from the previous year's filings.

Key Financial Figures

• $0.01 — ange on which registered Common stock, $0.01 par value POAI Nasdaq Capital Marke

Filing Documents

• poai20240331_10q.htm (10-Q) — 699KB
• ex_668497.htm (EX-31.1) — 12KB
• ex_668498.htm (EX-31.2) — 13KB
• ex_668499.htm (EX-32.1) — 6KB
• 0001171843-24-002875.txt (&nbsp;) — 4465KB
• poai-20240331.xsd (EX-101.SCH) — 47KB
• poai-20240331_def.xml (EX-101.DEF) — 310KB
• poai-20240331_lab.xml (EX-101.LAB) — 266KB
• poai-20240331_pre.xml (EX-101.PRE) — 339KB
• poai-20240331_cal.xml (EX-101.CAL) — 37KB
• poai20240331_10q_htm.xml (XML) — 600KB

FINANCIAL INFORMATION

PART I. FINANCIAL INFORMATION 4

UNAUDITED CONDENSED CONSOLIDATED FINANCIAL STATEMENTS

ITEM 1. UNAUDITED CONDENSED CONSOLIDATED FINANCIAL STATEMENTS 4 CONDENSED CONSOLIDATED BALANCE SHEETS AS OF MARCH 31, 2024, AND DECEMBER 31, 2023 4 CONDENSED CONSOLIDATED STATEMENTS OF NET LOSS FOR THE THREE MONTHS ENDED MARCH 31, 2024, AND 2023 5 CONDENSED CONSOLIDATED STATEMENTS OF STOCKHOLDERS' EQUITY FOR THE THREE MONTHS ENDED MARCH 31, 2024, AND 2023 6 CONDENSED CONSOLIDATED STATEMENTS OF CASH FLOWS FOR THE THREE MONTHS ENDED MARCH 31, 2024, AND 2023 8 NOTES TO CONDENSED CONSOLIDATED FINANCIAL STATEMENTS 9

MANAGEMENT'S DISCUSSION AND ANALYSIS OF FINANCIAL CONDITION AND RESULTS OF OPERATIONS

ITEM 2. MANAGEMENT'S DISCUSSION AND ANALYSIS OF FINANCIAL CONDITION AND RESULTS OF OPERATIONS 18

QUANTITATIVE AND QUALITATIVE DISCLOSURES ABOUT MARKET RISK

ITEM 3. QUANTITATIVE AND QUALITATIVE DISCLOSURES ABOUT MARKET RISK 22

CONTROLS AND PROCEDURES

ITEM 4. CONTROLS AND PROCEDURES 22

OTHER INFORMATION

PART II. OTHER INFORMATION 22

LEGAL PROCEEDINGS

ITEM 1. LEGAL PROCEEDINGS 22

RISK FACTORS

ITEM 1A. RISK FACTORS 22

UNREGISTERED SALES OF EQUITY SECURITIES AND USE OF PROCEEDS

ITEM 2. UNREGISTERED SALES OF EQUITY SECURITIES AND USE OF PROCEEDS 23

DEFAULTS UPON SENIOR SECURITIES

ITEM 3. DEFAULTS UPON SENIOR SECURITIES 23

MINE SAFETY DISCLOSURES

ITEM 4. MINE SAFETY DISCLOSURES 23

OTHER INFORMATION

ITEM 5. OTHER INFORMATION 23

EXHIBITS

ITEM 6. EXHIBITS 23

FINANCIAL INFORMATION

PART I. FINANCIAL INFORMATION

CONDENSED CONSOLIDATED FINANCIAL STATEMENTS

ITEM 1. CONDENSED CONSOLIDATED FINANCIAL STATEMENTS PREDICTIVE ONCOLOGY INC. CONDENSED CONSOLIDATED BALANCE SHEETS (Unaudited) March 31, 2024 December 31, 2023 ASSETS Current assets: Cash $ 5,197,235 $ 8,728,660 Accounts receivable 509,445 333,697 Inventories 441,718 494,374 Prepaid expense and other assets 412,925 521,700 Total current assets 6,561,323 10,078,431 Property and equipment, net 1,087,718 1,233,910 Intangibles, net 245,594 252,457 Lease right-of-use assets 2,582,456 2,728,355 Other long-term assets 124,096 124,096 Total assets $ 10,601,187 $ 14,417,249 LIABILITIES AND STOCKHOLDERS' EQUITY Current liabilities: Accounts payable $ 1,729,126 $ 1,342,027 Note payable 38,036 150,408 Accrued expenses and other liabilities 1,904,612 1,631,702 Derivative liability 367 1,376 Contract liabilities 304,320 308,091 Lease liability 540,200 517,427 Total current liabilities 4,516,661 3,951,031 Other long-term liabilities 3,507 5,459 Lease liability – net of current portion 2,027,348 2,188,979 Total liabilities 6,547,516 6,145,469 Commitments and contingencies Stockholders' equity: Preferred stock, 20,000,000 shares authorized inclusive of designated below Series B Convertible Preferred Stock, $ .01 par value, 2,300,000 shares authorized, 79,246 shares outstanding as of March 31, 2024, and December 31, 2023 792 792 Common stock, $ .01 par value, 200,000,000 shares authorized, 4,062,853 shares outstanding as of March 31, 2024, and December 31, 2023 40,629 40,629 Additional paid-in capital 175,992,976 175,992,242 Accumulated deficit ( 171,980,726 ) ( 167,761,883 ) Total stockholders' equity 4,053,671 8,271,780 Total liabilities and stockholders' equity $ 10,601,187 $ 14,417,249 See accompanying notes to unaudited condensed consolidated financial statements. 4 PREDICTIVE ONCOLOGY INC. CONDENSED CONSOLIDATED S

View Full Filing

View this 10-Q filing on SEC EDGAR